Tatva Chintan Pharma Chem growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+32.2%	+6.1%
EBITDA	+172.5%	+15.4%
Net Income	+637.1%	−2.6%
EPS (adj.)	+637.1%	−2.6%
Total Assets	+20.0%	+9.9%
Total Equity	+5.8%	+14.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

TATVA₹1,614.80

Tatva Chintan Pharma Chem Limited

· Chemicals

₹ CrorePeersVISHNU JUBLCPL KIRIINDUS FOSECOIND CHEMPLASTS DDEVPLSTIK GUJALKALI YASHOMcap ₹3,777 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+32.2	+6.1
EBITDA	+172.5	+15.4
Net Income	+637.1	-2.6
EPS (adj.)	+637.1	-2.6
Total Assets	+20.0	+9.9
Total Equity	+5.8	+14.9

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.